M&As this week: Illumina, Widex, Investindustrial

18 May 2018 (Last Updated May 18th, 2018 14:02)

Illumina Inc has completed the acquisition of Edico Genome Corp for $100m.

Illumina Inc has completed the acquisition of Edico Genome Corp for $100m.

The transaction will strengthen Illumina’s sequencing portfolio by adding Edico Genome’s DRAGEN platform to its product offerings.

Illumina is a developer of integrated systems for the analysis of genetic variation, while Edico Genome is a provider of data analysis acceleration solutions for next-generation sequencing (NGS).

Both the companies involved in the transaction are based in the US.

Widex A/S plans to merge with Sivantos Pte Ltd in a deal valued more than €7bn ($8.31bn).

The combined entity will be owned by EQT funds as well as co-investors and the Topholm and Westermann families of Denmark.

Based in Denmark, Widex is a hearing aids manufacturer, while Sivantos is also a hearing aids manufacturer based in Singapore.

The merger will enable the combined entity to accelerate growth, strengthen market penetration, and make investments in research and development (R&D).

“The merger will enable the combined entity to accelerate growth, strengthen market penetration, and make investments in research and development (R&D).”

Investindustrial SpA plans to acquire HTL-Strefa SA (HTL) from Sweden-based private equity firm EQT Partners AB.

HTL will be combined with PIC, the healthcare business of Artsana, which was acquired by Investindustrial in 2016.

Based in Italy, Investindustrial is an independent investment group, while HTL-Strefa is a medical device company based in Poland.

The transaction is expected to be closed in the third quarter of this year.

Zoetis Inc has signed an agreement to acquire Abaxis for $2bn, representing a price of $83 a share.

Based in the US, Zoetis is a provider of animal health business services, while Abaxis, also based in the US, is a developer, manufacturer and marketer of diagnostic instruments for veterinary point-of-care services.

The deal is subject to regulatory approvals and is expected to close in the fourth quarter of 2018.

The acquisition will enable Zoetis to strengthen its presence in the veterinary diagnostics market and accelerate its growth in more than 45 countries.